Journals / Retina-Vitreus / 2009 / Cilt: 17 - Sayı: 3

Efficacy of intravitreal bevacizumab injection for the treatment of macular edema secondary to retinal vein occlusion

Retina ven tıkanıklığına bağlı makula ödeminin tedavisinde intravitreal bevacizumab (Avastin®) enjeksiyonunun etkinliği

Pages
171–175
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, long-term studies are needed to determine the permanency of this anatomical and functional recovery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the functional and anatomical results after intravitreal bevacizumab injection in patients with macular edema secondary to retinal vein occlusion.
📊
Key Findings & Data:Material and Methods: Twenty-three eyes of 22 patients with macular edema secondary to retinal vein occlusion were treated with intravitreal bevacizumab injections (1.25 mg/0.05 ml) and enrolled in the study.
💡
Conclusion & Impact:However, long-term studies are needed to determine the permanency of this anatomical and functional recovery.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Göz içi basınç · Retinal ven tıkanıklığı · Geriyedönük çalışma

Abstract

Purpose: To evaluate the functional and anatomical results after intravitreal bevacizumab injection in patients with macular edema secondary to retinal vein occlusion. Material and Methods: Twenty-three eyes of 22 patients with macular edema secondary to retinal vein occlusion were treated with intravitreal bevacizumab injections (1.25 mg/0.05 ml) and enrolled in the study. These patients were evaluated with logMAR visual acuity, biomicroscopy, intraocular pressure, and optical coherence tomography results before and 1, 3, and 6 months after injection. Results: Twenty-three eyes of 22 patients with a mean age of 60.2 years (36-83) were enrolled in the study. Of the patients, 12 had central retinal vein occlusion and 11 had branch retinal vein occlusion. The mean logMAR visual acuity was 1.11±0.5 before the injection, and it was 0.87±0.6, 0.86±0.6, and 0.77±0.6 at 1, 3, and 6 months, respectively. There was a statistically significant visual acuity improvement during follow-up (p<0.05, paired t test) in separate groups as well. After treatment, visual acuity improved 2 or more lines in 8 eyes, less than 2 lines in 8 eyes, decreased in 1 eye, and there was no change in 6 eyes. Optical coherence tomography scans revealed that macular edema disappeared in 10 eyes, decreased in 12 eyes, and continued in 1 eye when compared with the baseline examinations. Mean follow-up was 7.32 months and mean number of injections during this period was 1.43 for these patients. Conclusion: In the short term, macular edema decreased and visual acuity increased after intravitreal injection of bevacizumab. However, long-term studies are needed to determine the permanency of this anatomical and functional recovery.

Özet

Amaç: Retina ven tıkanıklığına (RVT) bağlı makula ödemi tedavisinde intravitreal bevacizumab (Avastin®) enjeksiyonunun görme keskinliği ve anatomik sonuçlarının değerlendirilmesi. Gereç ve Yöntem: Retina ven tıkanıklığına bağlı makula ödemi olan ve intaravitreal bevacizumab (1.25 mg/0.05 ml) enjeksiyonu yapılan 22 olgunun 23 gözü retrospektif olarak çalışmaya dahil edildi. Olguların enjeksiyon öncesinde ve sonrası 1., 3. ve 6. ayda logMAR görme keskinliği, biyomikroskopi bulguları, göz içi basıncı ve optik koherens tomografi (OKT) sonuçları değerlendirildi. Bulgular: Ortalama yaşları 60.2 (36-83) yıl olan 22 olgunun 23 gözü çalışmaya dahil edildi. 12 gözde santral retinal ven tıkanıklığı (SRVT), 11 gözde ven dal tıkanıklığı (VDT) mevcuttu. Görme keskinliği enjeksiyon öncesi ortalama 1.11±0.5 logMAR iken 1. ayda 0.87±0.6, 3. ayda 0.86±0.6, 6.ayda ise 0.77±0.6 idi ve görme keskinliğinde tedavi öncesine göre tüm takip dönemlerinde istatistiksel olarak anlamlı fark saptandı (p<0.05, paired t testi). Bu anlamlılık SRVT ve VDT grupları ayrı olarak değerlendirildiğinde de mevcuttu (p<0.05, paired t testi). Tedavi sonrası görme keskinliğinde 8 gözde 2 sıra ve üstü artış, 8 gözde 2 sıra altında artış izlenirken 1 gözde görme keskinliğinde azalma oldu ve 6 gözde değişiklik izlenmedi. Enjeksiyonlar sonrası yapılan OKT sonucunda 10 gözde makula ödemi görülmezken, 12 gözde makula ödeminde enjeksiyon öncesine göre azalma ve 1 gözde ise ödemin devam ettiği gözlendi. Ortalama takip süresi 7.32 aydı ve bu sürede ortalama enjeksiyon sayısı 1.43 idi. Uygulamaya bağlı lokal yada sistemik komplikasyon görülmedi. Sonuç: Retina ven tıkanıklığına bağlı makula ödemi gelişen olgularda intravitreal bevacizumab enjeksiyonu sonrası erken dönemde makula ödemi azalmakta ve görme keskinliği korunmaktadır. Ancak bu anatomik ve fonksiyonel düzelmenin sürekliliğinin gösterilmesi için daha uzun süreli çalışmalara ihtiyaç vardır.

🔖

Cite This Article

EKEN, V., BATIOĞLU, F., ÖZMERT, E., DUMAN, R. (2009). Efficacy of intravitreal bevacizumab injection for the treatment of macular edema secondary to retinal vein occlusion. Retina-Vitreus, Cilt: 17 - Sayı: 3, 171–175. https://ajindex.com/articles/305149

References (15)

  1. Greer DV, Constable IJ, Cooper RL.: Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol. 1980;8:207-209
  2. The Branch Vein Occlusion Study Group.: Argon laser photocoagulation for macular oedema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-282
  3. The Central Vein Occlusion Study Group.: M report. Evaluation of grid pattern photocoagulation for macular oedema in central vein occlusion. Ophthalmology. 1995;102:1425-1433
  4. Mandelcorn MS, Nrusimhadevara RK.: Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. Retina. 2004;24:348-355
  5. Fekrat S, Goldberg MF, Finkelstein D.: Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol. 1998;116:43-52
  6. Weiss JN, Bynoe LA.: Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology. 2001;108:2249-2257
  7. Cekic O, Chang S, Tseng JJ, et al.: İntravitreal triamcinolone injection for treatment of macular oedema secondary to branch retinal vein occlusion. Retina. 2005;25:851-855
  8. Boyd SR, Zachary I, Chakravarthy U, et al.: Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central retinal vein occlusion. Arch Ophthalmol. 2002;120:1644-1645
  9. Avastin (Product monograph): Gardiner-Caldwell Communications Mississauga, Ontario: Hoffmann-La Roche Ltd. 2005
  10. Funatsu H, Yamashita H, Noma H, et al.: Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005;243:3-8
  11. Ng EW, Adamis AP.: Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352-368
  12. Aiello LP, Avery RL, Arrigg PG, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487
  13. Costa RA, Jorge R, Calucci D, et al.: Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBe- VO study. Retina. 2007;27:141-149
  14. Iturralde D, Spaide RF, Meyerle CB, et al.: Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279-284
  15. Pournaras JA, Nguyen C, Vaudaux JD, et al.: Treatment o